Adial pharmaceuticals announces greater than 50% of patients expected to complete onward™ phase 3 trial of ad04 for the treatment of alcohol use disorder have completed the full 24-week treatment period – trial completion anticipated q1 2022

Charlottesville, va., sept. 30, 2021 (globe newswire) -- adial pharmaceuticals, inc. (nasdaq: adil; adilw) (“adial” or the “company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announces that greater than 50% of patients expected to complete the onward™ phase 3 trial evaluating ad04 as a therapeutic agent for the treatment of alcohol use disorder (aud) in persons with certain target genotypes related to the serotonin transporter and receptor genes have completed the full, 24-week, treatment period.
ADIL Ratings Summary
ADIL Quant Ranking